Home › Funds › ELKHORN PARTNERS LIMITED PARTNERSHIP › BSX
ELKHORN PARTNERS LIMITED PARTNERSHIP position in BSX
BOSTON SCIENTIFIC CORP · Health Care
ELKHORN PARTNERS LIMITED PARTNERSHIP reported holding 3,800 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$166K, representing 0.14% of its reported portfolio and ranking #23 among its reported holdings. ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed BSX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ELKHORN PARTNERS LIMITED PARTNERSHIP's BSX position evolved
ELKHORN PARTNERS LIMITED PARTNERSHIP first disclosed a stake in BSX in Q2 2026 at 4,500 shares (US$192K). Across 2 filings, ELKHORN PARTNERS LIMITED PARTNERSHIP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,800 shares valued at US$166K — a reduction of -700 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.50K | $192.06K | New |
| Q3 2026 | 3.80K | $165.87K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- Janus Henderson Group 16.50M sh · $1.04B · Q1 2026
- Arrowstreet Capital 23.29M sh · $994.18M · Q2 2026
More on ELKHORN PARTNERS LIMITED PARTNERSHIP
FAQ
How long has ELKHORN PARTNERS LIMITED PARTNERSHIP held BSX?
ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed BSX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is ELKHORN PARTNERS LIMITED PARTNERSHIP's current position in BSX?
As of Q3 2026, ELKHORN PARTNERS LIMITED PARTNERSHIP holds 3.80K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $165.87K, representing 0.14% of its reported portfolio and ranking #23.
Has ELKHORN PARTNERS LIMITED PARTNERSHIP been buying or selling BSX?
In the latest 13F filing (Q3 2026), ELKHORN PARTNERS LIMITED PARTNERSHIP reduced its position in BSX.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.